ArticleJournal of proteome research2026
Optimized Simultaneous N/O-Glycopeptide Enrichment Strategy Identifies Lung Cancer Diagnostic Biomarkers in Serum.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycoproteins, degradable into glycopeptides, are crucial in lung cancer (LC), yet efficient methods to enrich them from LC serum for biomarker discovery remain lacking. We mixed microcrystalline cellulose with cationic and anionic fillers was packed into the DeepGP column. Comparing DeepGP, MAX, HILIC, and PBA in HeLa cells showed DeepGP's superior glycopeptide coverage, which was then applied to profile N/O-glycoproteins in 18 serum samples, with biomarker identification via MetaboAnalyst and N-glycan analysis using GlycanFinder. A total of 4801 glycopeptides (4021 N- and 780 O-glycopeptides) were quantified using MAX, HILIC, DeepGP, and PBA, with DeepGP identifying the most O-glycopeptides in HeLa cells. Applying DeepGP to LC serum enabled quantification of 10,482 N- and 11,110 O-glycopeptides. Proteomic analysis highlighted changes in transcription, post-translational modifications, protein turnover, and chaperone functions, with pathway enrichment revealing complement/coagulation cascades, cholesterol metabolism, and cancer-related proteoglycan signaling. MetaboAnalyst identified four site-specific glycopeptides (AACT-N106-H7N6S4F1, HEMO-N187-N4H5F1S1, ITIH3-N580-N5H6S3, IGG1-N180-N5H3F1) as potential biomarkers with AUC > 0.88. Thus, this establishes a refined strategy of DeepGP to simultaneously enrich N/O glycopeptides, enhancing the potential of glycopeptides as diagnostic and prognostic biomarkers for LC in clinical settings in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.